Abstract
Purpose :
To describe VF progression in glaucoma patients 1 year after a DH and explore the correlation with DH location and re-bleeding.
Methods :
30 patients with glaucoma and a DH were recruited at Moorfields Eye Hospital and followed for 5 visits over 1 year (0-1-3-6 and 12 months). In all visits patients had two 24-2 and two 10-2 VF (Humphrey Field Analyzer, Carl Zeiss Meditec, Inc., Dublin, CA), except on month 3 (only one of each). The Glaucoma Progression Analysis (GPA) software was used to establish progression at 1 year. Trend (MD and VFI for 24-2, MD for 10-2, overall and per hemifield (HF)) and event analyses were included. Progression on the HF corresponding to the DH was compared with the opposite HF. Progression rates were compared between ‘re-bleeders’ and ‘non re-bleeders’.
Results :
7 were excluded from analysis: 1 required surgery for progression in the study eye, 3 withdrew before 1 year, and 3 did not attend the last visit within the 1-year window due to COVID-related issues.
16 (70%) of DH were located in the inferior hemi-disc.
3 (13%) cases were labelled ’Possible progression’ on event-based analysis.
Mean MD (SD) at baseline were -3.39 (2.87) for 24-2 and -2.81 (4.22) for 10-2. Progression rates (SD) for MD were: -0.35 (1.6) in the superior HF and -0.27 (1.48) in the inferior HF (p=0.86), on 24-2 VF. On 10-2 VF, the rates were -0.93 (1.44) for the superior HF and -0.23 (0.93) for the inferior HF, p=0.06.
Progression rates in the HF corresponding to the DH vs the opposite HF were: -0.37 (1.74) vs -0.25 (1.32), p=0.79, on 24-2 and -0.82 (1.34) vs -0.34 (1.12), p=0.18, on 10-2.
16 (70%) patients re-bled in either eye during follow-up. Progression rates for re-bleeders vs non re-bleeders were: -0.33 (1.17) vs -0.24 (2.09), p=0.89, for 24-2 MD and -0.69 (1.11) vs -0.28 (0.9), p=0.41, for 10-2 MD.
Conclusions :
VF progression was fairly slow in our cohort and most patients remained stable on event analysis. There was a trend towards faster progression in the HF corresponding to the DH, but there was no statistically significant difference over this short observation period. Re-bleeding was common but was not associated with faster progression.
This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.